Amaç: İntragastrik Botulinum toksin A enjeksiyonunun, kilo kaybını indüklediği ve asetilkolin aracılı gastrik kasılmaların inhibisyonu sonucu gastrik motiliteyi yavaşlattığı gösterilmiştir. Bu çalışmanın amacı, obez hastalarda intragastrik botulinum toksin A enjeksiyonunun endoskopik intragastrik enjeksiyonlarının kilo kaybı üzerine etkilerini gözlemlemektir.
Gereç ve Yöntem: Toplam 400 U intragastrik botulinum toksin A enjeksiyonu endoskopik olarak midenin antrum, korpus ve fundus bölgelerine enjekte edildi. Vücut kitle indeksi değerlerine göre alt gruplara ayrılan 102 hastanın takip sonuçları ve kilo verme durumları değerlendirildi. Kilo kaybı verileri, birbirini izleyen üç ay boyunca aylık takip vizitlerinde kaydedildi.
Bulgular: Üçüncü ayın sonunda tüm hastaların vücut ağırlığında azalma gözlendi ve toplam ortalama kilo kaybı oranı %4,76-19,47 arasında değişti. Ortalama toplam vücut ağırlığı kaybı yüzdeleri Sınıf II ve III obez bireylerde normal ve aşırı kilolu ve Sınıf I obez bireylere göre anlamlı olarak daha yüksekti. Gastrointestinal yan etkiler hastaların sadece beşinde (%4,9) gözlendi.
Sonuç: 400 U’luk dozla intragastrik botulinum toksini enjeksiyonu uygulaması, farklı vücut kitle indekslerindeki bireylerde kilo kaybı amacıyla kullanımı uygun bir yöntemdir.
Background: Intragastric injection of Botulinum toxin A has been shown to induce weight loss, slowering gastric motility as a result of inhibition of the acetylcholine-mediated gastric contractions. The aim of this study was to observe the effects of endoscopic intragastric injections of intragastric injection of botulinum toxin A in obese patients.
Material and Method: A total dose of 400 U intragastric injection of botulinum toxin A was injected endoscopically into the antrum, corpus and fundus regions of the stomach. The follow-up results of 102 patients sub-grouped according to body mass indices values and evaluated the weight loss status were evaluated. Weight loss data was collected on the monthly follow-up visits for three consecutive months.
Results: At the end of the third month, all subjects lost body weight, with a mean total weight loss ratio ranging between 4.76-19.47%. Mean total body weight loss percentages were significantly higher in Class II and III obese subjects compared to the normal- and over-weight and Class I obese individuals. Gastrointestinal adverse effects were observed in only five (4.9%) of the patients.
Conclusion: Intragastric injection of botulinum toxin A administration with a dose of 400 U is a convenient method for weight loss for the individuals of different body mass indices.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Original Article |
Authors | |
Publication Date | June 18, 2020 |
Published in Issue | Year 2020 Volume: 3 Issue: 3 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.